Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

(2021) Messoud Ashina et al.   EUROPEAN JOURNAL OF NEUROLOGY

Hypertension: A new safety risk for patients treated with erenumab

(2021) Suprat Saely et al.   HEADACHE

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study

(2021) Michel Lanteri-Minet et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

(2021) David Kudrow et al.   BMC Neurology

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

(2021) Timothy R. Smith et al.   JOURNAL OF HEADACHE AND PAIN

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

(2020) David W Dodick et al.   CEPHALALGIA

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

(2020) Messoud Ashina et al.   CEPHALALGIA

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

(2020) Stewart J Tepper et al.   CEPHALALGIA

Eptinezumab: First Approval

(2020) Sohita Dhillon   DRUGS

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study

(2020) Roberto De Icco et al.   CEPHALALGIA

Galcanezumab for the prevention of cluster headache

(2020) Luca Giani et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

(2020) Håkan Ashina et al.   JOURNAL OF HEADACHE AND PAIN

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

(2020) Antonio Russo et al.   JOURNAL OF HEADACHE AND PAIN

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

One-year sustained efficacy of erenumab in episodic migraine

(2020) Peter J. Goadsby et al.   NEUROLOGY

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

(2020) Stephen Silberstein et al.   JOURNAL OF HEADACHE AND PAIN

LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY

(2020) Peter J. Goadsby et al.   NEUROLOGY

CGRP Monoclonal Antibody use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.

(2020) Kaitlin A. Greene et al.   PEDIATRIC NEUROLOGY

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab: from scientific evidence to clinical practice—the first Italian real-life data

(2019) Piero Barbanti et al.   NEUROLOGICAL SCIENCES

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

(2019) Valentina Favoni et al.   JOURNAL OF HEADACHE AND PAIN

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

(2019) William Kielbasa et al.   CEPHALALGIA

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

(2019) Yang Xu et al.   CNS DRUGS

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials

(2019) Virginia L. Stauffer et al.   HEADACHE

Consensus of the Brazilian Headache Society on the treatment of chronic migraine

(2019) Fernando KOWACS et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

(2019) Messoud Ashina et al.   CEPHALALGIA

Trial of Galcanezumab in Prevention of Episodic Cluster Headache

(2019) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

(2019) Michel D Ferrari et al.   LANCET

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

(2019) Jan Lewis Brandes et al.   CEPHALALGIA

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

(2019) Messoud Ashina et al.   CEPHALALGIA

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults

(2019) Fumihiko Sakai et al.   HEADACHE

Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine

(2019) Evangelos Kouremenos et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab safety and efficacy in migraine

(2019) Changyu Zhu et al.   MEDICINE

Vascular safety of erenumab for migraine prevention

(2019) David Kudrow et al.   NEUROLOGY

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

(2018) Jan de Hoon et al.   CEPHALALGIA

A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects

(2018) Orit Cohen-Barak et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Erenumab: First Global Approval

(2018) Anthony Markham   DRUGS

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

(2018) Christophe Depre et al.   HEADACHE

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment

(2018) Stewart J. Tepper   HEADACHE

Fremanezumab for preventive treatment of migraine

(2018) Juliana VanderPluym et al.   NEUROLOGY

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

(2018) Angelo Camporeale et al.   BMC Neurology

From LBR-101 to Fremanezumab for Migraine

(2018) Marcelo E. Bigal et al.   CNS DRUGS

Fremanezumab: First Global Approval

(2018) Sheridan M. Hoy   DRUGS

Galcanezumab: First Global Approval

(2018) Yvette N. Lamb   DRUGS

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

(2017) Joshua M. Cohen et al.   HEADACHE

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

(2017) Thuy Vu et al.   PHARMACEUTICAL RESEARCH

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

(2017) David Monteith et al.   Frontiers in Pharmacology

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab

(2017) Maria Giamberardino et al.   Journal of Pain Research

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Targeting CGRP: A New Era for Migraine Treatment

(2015) Stephanie Wrobel Goldberg et al.   CNS DRUGS

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

(2014) Marcelo E Bigal et al.   CEPHALALGIA

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain

(2014) R.J. Benschop et al.   OSTEOARTHRITIS AND CARTILAGE

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

(2013) Marcelo E Bigal et al.   CEPHALALGIA